Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial-Reference-Cited by-同舟云学术

Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial

Published:2015-08 Issue:8 Volume:15 Page:898-904
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Estívariz Concepción F,Anand Abhijeet,Gary Howard E,Rahman Mahmudur,Islam Jannatul,Bari Tajul I,Wassilak Steven G F,Chu Susan Y,Weldon William C,Pallansch Mark A,Heffelfinger James D,Luby Stephen P,Zaman Khalequ

Funder

Centers for Disease Control and Prevention

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference27 articles.

1. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review;Patriarca;Rev Infect Dis,1991

2. Eradicating polio: today's challenges and tomorrow's legacy;Aylward;Ann Trop Med Parasitol,2006

3. National immunization days: state of the art;Birmingham;J Infect Dis,1997

4. Optimal schedule for the administration of oral poliovirus vaccine;Patriarca,1993

5. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication;Caceres;Clin Infect Dis,2001

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial;Vaccine;2023-09

2. Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan;Vaccines;2023-09-01

3. Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial;The Lancet Infectious Diseases;2023-09

4. Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks;Vaccine;2023-04

5. Poliovirus Vaccine–Live;Plotkin's Vaccines;2023